Thus, these alterations remove at least some of the tumor-suppressive effects of TGFβ while retaining other tumor-promoting effects that include suppressing anti-tumor immune responses and inducing the production of pro-mitogenic factors in the tumor microenvironment2,3,6. The gene discussed is TGFB1; the disease is neoplasm.